SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO-Consultation on Obesity, Geneva, June 3–5, 1997. Geneva: WHO, 1998.
  • 2
    Hodge AM, Zimmer PZ. The epidemiology of obesity. Clin Endocrinol Metab 1994; 8: 57799.
  • 3
    Seidel JC. The worldwide epidemic of obesity. 8th International Congress on Obesity In: Guy-GrandB, AilhaudG, eds. Progress in Obesity Research, 8th edn. London: John Libbey, 1999: 6618.
  • 4
    Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Health CW Jr. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341(15): 1097104.
  • 5
    Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obesity 1992; 6: 397415.
  • 6
    Sjöström CD, Lissner L , Sjöström L. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Obesity Res 1997; 5: 51930.
  • 7
    Williamsen DF, Paumuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight-loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 1995; 141: 112841.
  • 8
    Bray GA. Coherent preventive and management strategies for obesity. In: ChadwickDJ, CardewG, eds. The Origins and Consequences of Obesity. London: John Wiley, 1996: 22846.
  • 9
    Wadden TA, Frey DL. A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: a five-year follow-up. Int J Eat Disord 1997; 22: 20312.
  • 10
    James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. The Lancet 2000; 356: 211925.
  • 11
    Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight-loss after a very-low-calorie diet: a randomised blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 17984.
  • 12
    Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet 1998; 352: 16061, 167–72.
  • 13
    Geliebter A. Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 1988; 44: 6658.
  • 14
    Schick RR, Schusdziarra V. Regulation of food intake. In: DitschuneitH, GriesFA, HaunerH, SchusdziarraV, WechslerJG, eds. Obesity in Europe 1993. London: John Libbey, 1994: 33548.
  • 15
    Sichick RR, Schusdziarra V, Schröder B, Classen M. Effect of intraduodenal or intragastric nutrient infusion on food intake in man. Z Gastroenterol 1991; 29: 63741.
  • 16
    Gonzalez MF, Deutsch JA. Vagotomy abolishes cues of satiety produced by gastric distention. Science 1981; 212: 12834.
  • 17
    Schick RR, Schusdziarra V. Appetit- und Sättigungsregulation. In: WechslerJG, ed. Adipositas — Ursachen und Therapie. Berlin and Wien: Blackwell, 1998: 11927.
  • 18
    Romieu I, Willett WC, Stampfer MJ, et al. Energy intake and other determinants of relative weight. Am J Clin Nutr 1988; 47: 40612.
  • 19
    Lissner L, Levitsky DA, Strupp BJ, Kalkwart HJ, Roe DA. Dietary fat and the regulation of energy intake in human subjects. Am J Clin Nutr 1987; 46: 88692.
  • 20
    Buzzard IM, Asp EH, Chlebowski RT, et al. Diet intervention methods to reduce fat intake: nutrient and food group composition of self-selected low-fat diets. J Am Diet Assoc 1990; 90(42–50): 53.
  • 21
    Brown GD, Whyte L, Gee MI, et al. Effects of two ‘lipid lowering’ diets on plasma lipid levels of patients with peripheral vascular disease. J Am Diet Assoc 1984; 84: 54650.
  • 22
    Katahn MR. The T-Factor Diet. New York: Norton, 1989.
  • 23
    McCarthy MF. The unique merits of a low-fat diet for weight control. Med Hypotheses 1986; 20: 18397.
  • 24
    Hammer RL, Barrier CA, Roundy ES, Bradford JM, Fisher AG. Calorie restricted low-fat diet and exercise in obese women. Am J Clin Nutr 1989; 49: 7785.
  • 25
    Schlundt DG, Hill JO, Pope-Cordle J, Arnold D, Wirths KL, Katahn M. Randomized evaluation of a low fat ad libitum carbohydrate diet for weight reduction. Int J Obesity 1993; 17: 6239.
  • 26
    Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 8285.
  • 27
    Heymsfield StB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 13216.
  • 28
    Hollander PA, Elbein StC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes — a 1-year randomized double-blind study. Diabetes Care 1998; 21: 128894.
  • 29
    Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat — a randomized controlled trial. J Am Med Assoc 1999; 281: 23542.
  • 30
    Finer N, James WPT, Kopelman PG, Lean MEJ, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obesity 2000; 24: 30613.
  • 31
    Hauptman J, Lucas Ch, Boldrin MS, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 1607.
  • 32
    Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69: 110816.
  • 33
    James WPT, Schofield EC. Human Energy Requirement: A Manual for Planners and Nutritionalists (published by arrangement with the Food and Agriculture Organization of the United Nations). Oxford: Oxford University Press, 1990.
  • 34
    Prentice AM, Goldberg S, Jebb SA. Physiological response to slimming. Proc Nutrition Soc 1991; 50: 44158.
  • 35
    Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose–response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 825.